Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label phase 3 trial of amphotericin B cholesterol sulfate complex for invasive candidiasis and invasive aspergillosis
ChiCTR2300068508Phase 3Not yet recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Mar 2023
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of amphotericin b cholesteryl sulfate complex in invasive candidiasis and invasive aspergillosis (IA), sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoints: Incidence of adverse events and Characteristics of adverse events. Planned start Mar 2023; status: not yet recruiting.
02
Drugs
amphotericin b cholesteryl sulfate complex
03
Conditions
invasive candidiasisinvasive aspergillosis (IA)
Beyond the preview
Go deeper on ChiCTR2300068508.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300068508.